WeTrade Group, a technical service provider of cloud intelligent systems for micro-businesses, has entered into a strategic alliance with Jiqing Biomedical to produce and provide exclusive sale channels for monkeypox virus test kits and antigen tests worldwide.

The partnership is also the beginning of WeTrade Group in the medical industry with an aim to develop domestic and international markets.

The bio-research and development team of Jiqing Bio has developed two monkeypox virus detection kits: nucleic acid test (RT-LAMP) and antigen test (colloidal gold technique) to help prevent and control the epidemic and detect the monkeypox infection cases.

Jiqing is a biotechnology company focusing on medical research and experimental development to use technological innovation at the forefront of its development to solve problems in key core areas.

WeTrade Group is known for digital tools such as WeChat mini programmes to help brands end the supply chain, traffic acquisition, product sales, and other issues.

The firm supports enterprises’ connections, serves users, expands the market, and helps to improve sales.

Through its partnership with Jiqing, WeTrade Group will provide the medical sector with advanced technology via YCloud’s industry accumulation in the fields of computer technology and big data.

Also, the company will leverage technical methods to develop SaaS platforms and data platforms to restructure the domestic medical industry’s pattern and aid in its standardisation of development.

WeTrade CEO Pijun Liu said: “The covid pandemic has caused tremendous harm to the public, and the monkeypox has caused a significant impact on people in several countries. To solve the issue, we are looking forward to the cooperation between us and Jiqing.

“We hope to bring the two monkeypox virus test kits to the market as soon as possible by technology empowerment, to help prevent and control the virus, and to reduce the harm for the public worldwide.”